Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05810025 · ClinicalTrials.gov registry record · NA

FHIR-Enhanced RealRisks to Improve Accuracy of Breast Cancer Risk Assessments

A NA study, sponsored by Columbia University.

Completed
Registry status
NA
Development phase
70
Enrollment target

NCT05810025: Completed NA study, sponsored by Columbia University.

NCT05810025 is a NA study that has completed, run by Columbia University. The registered enrollment target is 70 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05810025, a NA study, has completed, sponsored by Columbia University.

COMPLETED
Registry status
NA
Development phase
70 participants
Enrollment target

Study Summary

Electronic health records (EHRs) are an increasingly common source for populating risk models, but whether used to populate validated risk assessment models or to de-facto build risk prediction models, EHR data presents several challenges. The purpose of this study is to assess how the integration of patient generated health data (PGHD) and EHR data can generate more accurate risk prediction models, advance personalized cancer prevention, improve digital access to health data in an equitable manner, and advance policy goals for Patient Generated Health Data (PGHD) and EHR interoperability.

Primary Outcome

Validated 13-item Patient Activation Measure, which measures patient knowledge, skill, and confidence in self-management of health. Scores range from 0 to 100; higher scores indicate greater activation.

Interventions

  • BEHAVIORAL RealRisks

Trial Details

FieldValue
Enrollment Target 70 participants
Start Date 2023-05-01
Est. Completion 2025-12-31
Phase NA
Columbia University

958 total trials

What the finished NCT05810025 record still lists

NCT05810025 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower).

The record links to 0 conditions, and to 1 intervention - of which RealRisks is the first listed.

NCT05810025 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT05810025 about?

NCT05810025 is a clinical study titled "FHIR-Enhanced RealRisks to Improve Accuracy of Breast Cancer Risk Assessments". Electronic health records (EHRs) are an increasingly common source for populating risk models, but whether used to populate validated risk assessment models or to de-facto build risk prediction models, EHR data presents several challenges. The purpose of this study is to assess how the integration o...

What is the current status of trial NCT05810025?

This trial is currently completed. It is a NA study. The enrollment target is 70 participants. The study started on 2023-05-01. Estimated completion is 2025-12-31.

What interventions are being tested in trial NCT05810025?

The interventions under investigation include: RealRisks (BEHAVIORAL).

Who is sponsoring clinical trial NCT05810025?

This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT05810025's enrollment target sits among peer trials

70 1103rd of 2000 higher than 868 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00969111 · 70 participants · NA

    Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy

  • NCT01712620 · 70 participants · Phase 2

    Spironolactone for Pulmonary Arterial Hypertension

  • NCT02143830 · 70 participants · Phase 2

    HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy

  • NCT02601339 · 70 participants

    NIRS Monitoring in Premature Infants

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05810025, the US trial registry maintained by the National Library of Medicine. NCT05810025 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.